H.C. Wainwright reiterates Buy rating on Personalis stock at $8.50

Investing.com - H.C. Wainwright has reiterated its Buy rating and $8.50 price target on Personalis (NASDAQ:PSNL), currently trading at $5.24, following clinical data presented at the 2025 World Conference on Lung Cancer. The company, with a market capitalization of $465 million, has seen its stock surge over 26% in the past six months. According to InvestingPro data, analyst targets range from $5 to $9 per share.

The data update from the Phase 3 NeoADAURA study was jointly presented by Personalis and AstraZeneca on September 7. The study evaluated osimertinib (TAGRISSO) as a neoadjuvant therapy in patients with resectable EGFR-mutated stage II-IIIb non-small cell lung cancer. InvestingPro analysis shows the company maintains strong liquidity with a current ratio of 6.09, holding more cash than debt on its balance sheet.

The pre-planned exploratory analysis evaluated plasma samples from patients using Personalis’ NeXT Personal, an ultra-sensitive circulating tumor DNA-based molecular residual disease assay to predict efficacy outcomes.

Results demonstrated that baseline molecular residual disease status could serve as a prognostic indicator for the efficacy of osimertinib neoadjuvant therapy in this patient population.

H.C. Wainwright maintained its 12-month price target of $8.50 per diluted share on Personalis stock based on these findings.

In other recent news, Personalis Inc . reported its second-quarter 2025 earnings, showing a mixed financial performance. The company recorded an earnings per share (EPS) of -$0.23, slightly surpassing the forecast of -$0.24. However, revenue came in at $17.2 million, falling short of the expected $20.07 million, representing a 14.3% miss. Additionally, Personalis announced new data from its NeXT Personal molecular residual disease (MRD) test, which effectively predicts outcomes in patients with EGFR-mutated non-small cell lung cancer. These findings are part of AstraZeneca’s phase 3 NeoADAURA clinical trial. The detailed results will be presented at the IASLC 2025 World Conference on Lung Cancer in Barcelona.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.